Nothing Special   »   [go: up one dir, main page]

BR112014014917A2 - inibidores de fusão da membrana do hiv - Google Patents

inibidores de fusão da membrana do hiv

Info

Publication number
BR112014014917A2
BR112014014917A2 BR112014014917A BR112014014917A BR112014014917A2 BR 112014014917 A2 BR112014014917 A2 BR 112014014917A2 BR 112014014917 A BR112014014917 A BR 112014014917A BR 112014014917 A BR112014014917 A BR 112014014917A BR 112014014917 A2 BR112014014917 A2 BR 112014014917A2
Authority
BR
Brazil
Prior art keywords
hiv
membrane fusion
fusion inhibitors
hiv membrane
amino acids
Prior art date
Application number
BR112014014917A
Other languages
English (en)
Inventor
Albert Malcolm Bruce
Francis Robert Nestor Buyck Christophe
Wouter Slootstra Jelle
Wilhelmus J Thuring Johannes
Aldegonda Jacoba Kriek Maria
Timmerman Peter
Martinus Maria Schaaper Wilhelmus
Bert Griet Schepens Wim
Original Assignee
Janssen R&D Ireland
Pepscan Systems Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen R&D Ireland, Pepscan Systems Bv filed Critical Janssen R&D Ireland
Publication of BR112014014917A2 publication Critical patent/BR112014014917A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

resumo patente de invenção: "inibidores de fusão da membrana do hiv". a presente invenção refere-se a um inibidor de fusão do vírus da imunodeficiência humana (hiv) com, ou entrada do hiv em, uma célula hospedeira compreendendo pelo menos 24, mas preferencialmente 26, aminoácidos contíguos; a invenção também se refere a uma composição farmacêutica compreendendo os ditos aminoácidos.
BR112014014917A 2011-12-19 2012-12-18 inibidores de fusão da membrana do hiv BR112014014917A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11194340 2011-12-19
PCT/EP2012/075956 WO2013092591A1 (en) 2011-12-19 2012-12-18 Hiv membrane fusion inhibitors

Publications (1)

Publication Number Publication Date
BR112014014917A2 true BR112014014917A2 (pt) 2018-05-15

Family

ID=47501221

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014014917A BR112014014917A2 (pt) 2011-12-19 2012-12-18 inibidores de fusão da membrana do hiv

Country Status (8)

Country Link
US (1) US20140357577A1 (pt)
EP (1) EP2794636A1 (pt)
JP (1) JP2015502378A (pt)
CN (1) CN104159914A (pt)
BR (1) BR112014014917A2 (pt)
IN (1) IN2014MN01384A (pt)
RU (1) RU2014129907A (pt)
WO (1) WO2013092591A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9670250B2 (en) * 2012-04-27 2017-06-06 The Trustees Of The University Of Pennsylvania Alpha-helical peptidomimetic inhibitors and methods using same
CN109320593A (zh) * 2018-11-05 2019-02-12 中国人民解放军军事科学院军事医学研究院 抑制hiv感染的螺旋多肽及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339069B1 (en) * 1996-10-15 2002-01-15 Elan Pharmaceuticalstechnologies, Inc. Peptide-lipid conjugates, liposomes and lipsomal drug delivery
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
US20080025977A1 (en) * 2003-04-14 2008-01-31 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
JP2007517522A (ja) * 2004-01-07 2007-07-05 トリメリス，インコーポレーテッド ＨＩＶｇｐ４１ＨＲ２由来の合成ペプチド、およびヒト免疫不全ウイルスの伝播を阻止する治療におけるその使用
PL1844337T3 (pl) * 2005-01-24 2013-12-31 Pepscan Systems Bv Związki wiążące, związki immunogenne i peptydomimetyki
WO2007097903A2 (en) * 2006-02-02 2007-08-30 Trimeris, Inc. Hiv fusion inhibitor peptides with improved biological properties
US20080131428A1 (en) * 2006-02-24 2008-06-05 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
JP2009528355A (ja) * 2006-02-28 2009-08-06 トラスティーズ オブ ボストン ユニバーシティ 代謝調節因子およびその使用
JP2009529007A (ja) * 2006-02-28 2009-08-13 イーライ リリー アンド カンパニー 選択的ｖｐａｃ２受容体ペプチドアゴニスト
GB0720503D0 (en) * 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound

Also Published As

Publication number Publication date
EP2794636A1 (en) 2014-10-29
RU2014129907A (ru) 2016-02-10
WO2013092591A1 (en) 2013-06-27
IN2014MN01384A (pt) 2015-04-03
CN104159914A (zh) 2014-11-19
JP2015502378A (ja) 2015-01-22
US20140357577A1 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
BR112018075465A2 (pt) agentes antivirais de hepatite b
BR112014009146A2 (pt) formulações de etanercepte estabilizadas com aminoácidos
BR112018067964A2 (pt) agentes antivirais para hepatite b
BR112013031268A2 (pt) "polipeptídeos análogos de pramlintida, uso dos mesmos, composição farmacêutica compreendendo os referidos polipeptídeos e método de preparação da referida composição".
EA201692443A1 (ru) Водная фармацевтическая композиция тапентадола для перорального введения
EA201391236A1 (ru) Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов
BR112014000938A2 (pt) quinazolinas substituídas, a preparação das mesmas e o uso das mesmas em composições farmacêuticas
BR112015010908A2 (pt) derivado de pirrol sulfonamida, método de preparação para o mesmo e aplicação médica do mesmo
BR112014011162A2 (pt) derivados purínicos para o tratamento de infecções virais
BR112015001101A2 (pt) formas cristalinas de um inibidor de prolil hidroxilase
CO6771409A2 (es) Acidos 1-bencilcicloalquilcarboxilicos sustituidos y su uso
BR112016010383A2 (pt) compostos de pyy seletivos e usos dos mesmos
CO7240369A2 (es) Ácido 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
BR112013000920A2 (pt) compostos para a redução de produção de beta-amiloide
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
WO2012140127A3 (en) Method for priming of t cells
BR112013030894A2 (pt) moduladores do sistema imune
BR112015018838A2 (pt) estabilidade melhorada de novas composições líquidas
EP3363458A3 (en) A peptide
BR112014014452A2 (pt) derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
BR112015018504A2 (pt) moduladores de flap
BR112013004662B8 (pt) Composto, composição farmacêutica, usos de um composto, e método para preparar uma composição farmacêutica
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
BR112013030391A2 (pt) derivados de piperidina 3- espirocíclicos como agonistas dos receptores de grelina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: PEPSCAN SYSTEMS BV (NL) ; JANSSEN SCIENCES IRELAND

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2472 DE 22-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.